Polyneuron is a pharmaceutical company, committed to the development of a new drug class for the treatment of autoimmune disorders.
Polyneuron Pharmaceuticals AG has raised €33M across 2 funding rounds from 2 investors, most recently a Series A round in Sep 2020. Based in Basel, Switzerland; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2020-09-16 | Series A | €13M | — | View deal → |
| 2019-01-01 | Other | €20M | New Enterprise Associates,Sofinnova Partners | View deal → |
